MedTrace Logo

Study on Lixisenatide and Counterregulation to Hypoglycemia

NCT02020629 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2015-12-15

No results posted yet for this study

Summary

In hypoglycemia, there is a counterregulation to restore glucose levels. An important part of this counterregulation is the release of the hormone glucagon. Since the GLP-1 receptor agonist lixisenatide has been shown to be associated with a low risk of hypoglycemia, this study examines whether lixisenatide affects the glucagon response to hypoglycemia.

Conditions

Interventions

DRUG

Lixisenatide

Lixisenatide is given for 6 weeks whereafter a hypoglycemia clamp is undertaken

Sponsors & Collaborators

  • Lund University

    lead OTHER

Principal Investigators

  • Bo Ahrén, MD, PhD · Lund University

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2014-08-31
Completion
2015-08-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02020629 on ClinicalTrials.gov